CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 107,383 enrolled
Drug / intervention
Apixabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04681482
NCT04681482N/ACompleted
CompareCT.gov

Effectiveness and Safety of Oral Anticoagulants Among Obese Patients With Non-Valvular Atrial Fibrillation in the Veterans Affairs Population With Medicare

Pfizer·observational·Posted Dec 23, 2020·Updated May 22, 2023

In Brief

An observational study evaluating Apixaban for Atrial Fibrillation and 2 related conditions. Completed, enrolled 107,383 participants across 1 site.

Detailed Summary

The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who initiate therapy with OACs (oral anti-coagulants). The aim of this study is to compare all DOACs (direct oral anti-coagulants) to warfarin. However, the primary analysis will be conducted among apixaban vs warfarin patients only. If sample size permits, we will also conduct other DOAC vs warfarin and DOAC vs DOAC analysis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Obesity, Anticoagulants
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedDec 23, 2020
Enrollment StartNov 2, 2020
Primary CompletionNov 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 5.5 years ago

Interventions

Apixabandrug

Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.